Adverse Reactions and Safety Profile of CAMZYOS

The safety profile of CAMZYOS is characterized by a higher incidence of dizziness (27%) and syncope (6%) compared to placebo. Heart failure due to systolic dysfunction is a significant risk, necessitating prompt interruption of therapy if LVEF falls below 50% or if symptoms worsen. Other adverse effects include hypotension and, rarely, asystole in overdose scenarios. CAMZYOS may also interact with other drugs, leading to increased or decreased efficacy or toxicity. Adverse effects in pediatric, pregnant, or lactating patients are not specified in the description.